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Cerebral sinovenous thrombosis (CSVT) is a rare disease in the neonatal 
period and also the greatest risk of neonatal mortality and morbidity. In this 
report, we presented two cases with CSVT and different risk factors. One 
of these cases had methylenetetrahydrofolate reductase (MTHFR) C677T 
homozygous polymorphism and the other case had both MTHFR A1298C 
homozygous polymorphism, plasminogen activator inhibitor-1 (PAI-1) 4G/ 
5G polymorphism and elevated lipoprotein a. Early diagnosis and prompt 
initiation of therapy of neonatal CSVT may prevent neonatal mortality and 
poor long-term neurodevelopmental outcomes.
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Cerebral sinovenous thrombosis (CSVT) is a 
rare disease in the neonatal period and also 
the greatest risk of neonatal mortality and 
morbidity. Symptoms are usually nonspecific 
and may present as seizures, respiratory 
distress, lethargy, jitteriness, dilated scalp veins, 
poor feeding, hemiparesis and hemiplegia. 
Seizures are the most common neurologic 
symptom in neonatal CSVT, while symptoms 
related to intracranial hypertension and focal 
neurologic signs are more frequent in children. 
In this report, we presented two cases with 
CSVT and different risk factors. One of 
these cases had methylenetetrahydrofolate 
reductase (MTHFR) C677T homozygous 
polymorphism and the other case had both 
MTHFR A1298C homozygous polymorphism, 
plasminogen activator inhibitor-1 (PAI-1) 4G/ 
5G polymorphism and elevated lipoprotein a. 
Case Reports
Case 1 
A 41-year-old, gravida 1 mother delivered a 
male baby at a gestational age of 33 weeks by 
cesarean section, with a birth weight (BW) of 
2,240 g. Apgar scores were 8 and 9 at 1 and 5 
minutes, respectively. There was no history of 
maternal disease in uncomplicated pregnancy. 
Parents were not consanguineous. Transposition 
of the great arteries (TGA) was detected at 
the 26th week on the fetal echocardiography. 
His physical examination was normal except 
for pansystolic heart murmur on mesocardiac 
focus. He was intubated and started intravenous 
prostaglandin infusion. Echocardiography 
revealed TGA, muscular ventricular septal 
defect (VSD) and patency of ductus arteriosus 
(PDA). Septostomy was performed on the 
second day of life. On the postnatal third day, 
the patient had focal seizures on the left arm. 
He was given phenobarbital and no seizure was 
observed afterwards. Complete blood count, 
biochemical parameters, C- reactive protein 
level, EEG scan, transfontanelle and abdominal 
ultrasonography were normal. Protein C, total 
protein S, antithrombin III, factor I, VII, VIII, 
XII and von Willebrand factor levels were 
normal. The lupus anticoagulant, anticardiolipin 
antibody, anti dsDNA and ANA levels were 
negative. The magnetic resonance imaging 
(MRI) and MRI venography scan of the brain 
showed thrombotic lesions in the superior 
sagittal sinus and the both transverse sinuses, 
in addition to few and very tiny spots of 
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hemorrhage in the cortico medullary junction 
and diffuse edema in the periventricular white 
matter (Fig. 1). Although the dimensions of 
the hemorrhagic spots were very small (in 
milimetric dimensions) and not significant. He 
was started on subcutaneous low molecular 
weight heparin (LMWH), 150 U/kg, twice 
daily adjusting the dose to keep the anti 
factor Xa level between 0.5-1.0 U/ml. He had 
homozygous MTHFR C677T polymorphism. 
Homocysteine level was normal. All diagnostic 
laboratory studies for thrombophilia were 
presented in Table I.
The control brain MRI taken after 2 weeks 
showed a minimal residual thrombosis in the 
left transverse sinus and disappearence of 
tiny hemorrhagic spots. He underwent TGA 
correction (Jaten) operation on the 29th day 
of life. Since brain MRI scan taken in the 3rd 
month was normal, LMWH and anticonvulsant 
were stopped on the third month of life. 
Prophylactic treatment was not given. He is 
now 11 months old without any neurologic 
deficits. 
Case 2
A 20-year-old, gravida 1 mother delivered a 
male baby at a gestational age of 38 weeks 
by cesarean section, with a BW of 3,700 g. 
Apgar scores were unknown. The patient was 
discharged from another hospital on the second 
day of life. There was no history of prenatal 
problems and maternal disease. Parents were 
not consanguineous. When he was admitted to 
our hospital on the eighth day of life, he was 
dehydrated (weight loss 29%), had lethargy, 
anuria and poor neonatal reflexes. He could 
not be fed by breast milk or other formulated 
feedings properly. The initial laboratory findings 
were as follows: blood sodium 186 mEq/L, 
potassium 7.4 mEq/L, creatinine 4.8 mg/
dl, hemoglobin 16 g/dl, haematocrit 54%, 
MCV108/ fL, WBC 12,700/mm3, platelets 
435,000/mm3. Protein C, total protein S, 
antithrombin III, factor I, VII, VIII, XII and 
von Willebrand factor levels were normal. The 
lupus anticoagulant, anticardiolipin antibody, 
anti dsDNA and ANA levels were negative. 
Transfontanelle ultrasonography was normal. 
Renal ultrasonography revealed medullary 
nephrocalcinosis. The MRI and MRI venography 
scan of the brain showed thrombotic lesions 
in both transverse sinuses (Fig. 2). 
He was started on subcutaneous LMWH as 
150 U/kg twice daily, adjusting the dose to 
keep the anti factor Xa level between 0.5-
1.0. The brain computed tomography (CT) 
taken on the 3rd day of LMWH treatment 
showed no hemorrhage. He had homozygous 
MTHFR A1298C polymorphism and PAI 4G/5G 
polymorphism, and elevated lipoprotein a. 
Other diagnostic tests for thrombophilia were 
presented in Table I. The brain MRI taken after 
8 weeks of therapy revealed that the thrombosis 
had resolved completely. Total duration of 
acute anticoagulation therapy was 2 months 
and prophylactic treatment was not given. 
Due to mild vitamin B12 deficiency, vitamin 
B12 therapy was started. Neurologic signs 
were irrelevant to vitamin B12 deficiency. He 
is now 6 months old without any neurologic 
deficits. Informed consent was received from 
the families.
Discussion 
Cerebral sinovenous thrombosis is an 
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Diagnostic Tests Case 1 Case 2 
Homocysteine, µmol/L (normal: 5.46-14) 6.47 7.7
Vitamin B12, pg/ml (normal: 138-652) 405 209
Folic acid, ng/ml (normal: 3.1-20.5) 13.7 12
Factor V Leiden Homozygous normal Homozygous normal
Prothrombin 20210A Homozygous normal Homozygous normal
MTHFR C677T polymorphism Homozygous mutant Homozygous normal
MTHFR A1298C polymorphism Homozygous normal Homozygous mutant
PAI-1 (4G/5G) polymorphism 5G/5G 4G/5G
d-dimer, ug/ml (normal: <0.5) 3.84 0.36
Table I. Diagnostic Tests for Thrombophilia of Two Cases
MTHFR: methylenetetrahydrofolate reductase, PAI: plasminogen activator inhibitor-1
uncommon disease in children. The true 
incidence of CSVT is unknown in neonates 
and children. Although likely underestimated, 
CSVT occurs in about one of 100,000 children 
per year and approximately half of the CSVT 
in children occur in the neonatal period or in 
early infancy. Important risk factors causing 
CSVT in newborns include congenital heart 
disease (TGA), perinatal hypoxic ischemic 
encephalopathy, meconium aspiration syndrome, 
Apgar score <7 at 5 minute, intubation at 
birth, postnatal sepsis, meningitis, dehydration, 
polycythemia, pneumonia, ECMO treatment, 
disseminated intravascular coagulation, 
congenital diaphragmatic hernia, placental 
premature rupture of membranes, ablatio 
plasenta, chorioamnionitis and maternal 
gestational diabetes mellitus and preeclampsia, 
hypertension problems1-3.
Other risk factors are presence of prothrombotic 
states l ike factor V G1691A (Leiden) 
mutation, prothrombin G20210A mutation, 
protein C, protein S and antithrombin III 
deficiencies, elevated lipoprotein (a) levels and 
anticardiolipin antibodies, increased factor VIII 
level, hyperhomocyteinemia and homozygosity 
for thermolabile variant of the MTHFR gene, 
homocystinuria2,4. Prothrombotic states were 
detected in 20% of neonates and 24-64% of 
children with CSVT2. Herein, we presented 
two CSVT cases with two different gene 
polymorphisms and risk factors. 
C677T polymorphism is the most common 
mutation in MTHFR polymorphism. Catalano 
et al.5 found that MTHFR A1298C gene 
heterozygous polymorphism had more severe 
non-alcoholic fatty liver disease. There has been 
very rarely reported case of CSVT associated 
with MTHFR A1298C mutation in the neonatal 
period. Homozygoous mutation for MTHFR 
A1298C with CSVT has been previously 
reported in a newborn infant6. In this case, 
clinical presentation was seizure but had no 
other risk factors for CSVT. MTHFR gene 
mutation analysis noted a positive C677T 
homozygous mutation and MTHFR A1298C 
homozygous mutation in our patients. In 
addition to MTHFR mutations, our first 
case had congenital heart disease and post 
catheterization procedure for septostomy. Our 
second case had hypernatremic dehydration, PAI 
4G/5G polymorphism, and elevated lipoprotein 
a levels which is also risk factor for arterial 
thrombosis7. While the first patient had 
three, the second patient had four risk factors 
for venous thrombosis. Hence, at least one 
risk factor has been identified in more than 
90% of patients in children with CSVT. Lolli 
et al.7 reported that no predisposing factor 
was significantly higher in newborn infants 
than older children (36% and less than 5%, 
respectively). 
Fig. 2. The magnetic resonance imaging (MRI) venography 
scan of the brain showed thrombotic lesions in the both 
transverse sinuses
Fig. 1. The magnetic resonance imaging (MRI) venography 
scan of the brain showed thrombotic lesions in the superior 
sagittal sinus and the both transverse sinuses
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PAI-1 inhibits the activity of urokinase 
plasminogen activator, which plays an essential 
role for the cleavage of plasminogen to plasmin. 
PAI 4G/5G polymorphism is a common 
polymorphism in the promoter region of the PAI-
1 gene. This polymorphism is associated with 
a slightly increased risk of thromboembolism. 
Our second case is the first reported neonatal 
CSVT with homozygotic MTHFR A1298C and 
PAI 4G/5G polymorphism. Onrat et al.8 also 
reported that the PAI 4G/5G polymorphism 
is associated with myocardial infarction in 
patients before the age of 45.
Hyperhomocysteinemia is a common result of 
MTHFR polymorphism9. MTHFR polymorphism 
is  not  inc luded in  the  guide l ines  o f 
thrombophilia among laboratory tests. However, 
new data suggest that only homocysteinemia 
or thermolabile variant of MTHFR should be 
investigated1,10. 
However, stroke in both C677T and MTHFR 
A1298C mutations were reported not to 
be associated with hyperhomocysteinemia. 
This was attributed to that single time-point 
measurements may not be enough to represent 
overall homocysteine abnormalities and 
homocysteine levels fluctuated with time9,11. 
Therefore, normal levels of homocysteine 
in single measurements does not rule out 
hyperhomocysteinemia in our patients.
The best form of treatment for neonatal 
CSVT is unknown. Although not based on 
clinical trials, unfractionated heparin or LMWH 
administration is therefore advised in patients 
with SVT for a minimum period of 6 weeks 
and no longer than 3 months. At the present 
time, anticoagulant therapy is safe in neonatal 
CSVT cases12.
A meta-analysis showed that mortality was 
significantly reduced in children/neonates 
who received anticoagulation as 1.8% vs 
10%. Anticoagulation seemed also to predict 
reduction in thrombosis and total or partial 
sinus recanalization, both associated with a 
reduced risk of a new infarct and an improved 
clinical outcome13. Anticoagulation therapy 
is less frequently used in neonates. Two 
determinants of unfavourable outcome as 
death or sequelae in children with CSVT 
were reported as neonatal age and absence 
of anticoagulation therapy13. Thorell et al.14 
showed heparin treatment reduced mortality 
and severe disability with no increase in risk 
of intracranial hemorrhage. In the Canadian 
registry of CSVT over one third of newborns 
with CSVT received anticoagulant medications 
without major bleeding or extension of the 
thrombus12. In our patients, we administered 
LMWH since Case 2 did not have hemorrhage, 
and Case 1 did not have significant hemorrhage 
being only as few and very tiny spots of 
hemorrhage. We did not experience any 
hematological or neurological complications 
with LMWH.
Abnormal neurodevelopmental outcomes have 
been revealed in 40% to 80%. The spectrum 
of neurological disabilities reported in previous 
studies also varied (developmental delay, 
epilepsy, cerabral palsy, hydrocephalus) but is 
suggestive of global impairment of function 
with more severe impairments 3,15-17. Gentilomo 
et al.17 reported that neurological sequelae 
were significantly higher in prothrombotic 
abnormalities group compared to the without 
thrombophilic disease. Bektaş et al.15 showed 
that newborns who did not receive anticoagulant 
therapy were often worse neurologic outcome.
Cerebra l  s inovenous thrombosis  is  a 
multifactorial and life threatening disease. 
Treatment of underlying causes like sepsis, 
dehydration, congenital heart disease is very 
important in protrombotic disorder. Early 
diagnosis and prompt initiation of therapy of 
neonatal CSVT may prevent neonatal mortality 
and poor long-term neurodevelopmental 
outcomes.
REFERENCES
1. Roach ES, Golomb MR, Adams R, et al. American Heart 
Association Stroke Council; Council on Cardiovascular 
Disease in the Young. Management of stroke in infants 
and children: a scientific statement from a Special 
Writing Group of the American Heart Association 
Stroke Council and the Council on Cardiovascular 
Disease in the Young. Stroke 2010; 39: 2644-2691.
2. Dlamini N, Billinghurst L, Kirkham FJ. Cerebral venous 
sinus (sinovenous) thrombosis in children. Neurosurg 
Clin N Am 2010; 21: 511-527.
3. deVeber G, Andrew M, Adams C, et al. Canadian 
Pediatric Ischemic Stroke Study Group. Cerebral 
sinovenous thrombosis in children. N Engl J Med 
2001; 9: 417-423.
4. Heller C, Heinecke A, Junker R, et al. Childhood 
Stroke Study Group. Cerebral venous thrombosis in 
children: a multifactorial origin. Circulation 2003; 108: 
1362-1367.
74    Turan Ö,  et  al  The Turkish  Journal  of  Pediatrics  •  January-February  2017
5. Catalano D, Trovato GM, Ragusa A, et al. Non-alcoholic 
fatty liver disease (NAFLD) and MTHFR 1298A > C 
gene polymorphism. Eur Rev Med Pharmacol Sci 2014; 
18: 151-159.
6. Cizmeci MN, Kanburoglu MK, Akelma AZ, et al. 
Cerebral sinovenous thrombosis associated with 
MTHFR A1298C mutation in the newborn: a case 
report. J Thromb Thrombolysis 2013; 35: 279-281. 
7. Lolli V, Molinari F, Pruvo JP, Soto Ares G. Radiological 
and clinical features of cerebral sinovenous thrombosis 
in newborns and older children. J Neuroradiol 2016; 
43: 280-289.
8. Onrat ST, Akci O, Söylemez Z, Onrat E, Avşar A. 
Prevalence of myocardial infarction polymorphisms in 
Afyonkarahisar, Western Turkey. Mol Biol Rep 2012; 
39: 9257-9264.
9. Rook JL, Nugent DJ, Young G. Pediatric stroke and 
methylenetetrahydrofolate reductase polymorphisms. 
An examination of C677T and A1298C mutations. J 
Pediatr Hematol Oncol 2005; 27: 590-593.
10. Raffini L. Thrombophilia in children: Who to test, 
how, when, and why? Hematology Am Soc Hematol 
Educ Program 2008; 228-235.
11. Solomon LR. Cobolamin-responsive disorders in the 
ambulatory care setting: unreliability of cobalamin, 
methylmalonic acid, and homocysteine testing. Blood 
2005; 105: 978-985.
12. Moharir MD, Shroff M, Stephens D, et al. Anticoagulants 
in pediatric cerebral sinovenous thrombosis: a safety 
and outcome study. Ann Neurol 2010; 67: 590-599.
13. Lebas A, Chabrier S, Fluss J, et al. French Society for 
Paediatric Neurology; European Paediatric Neurology 
Society. EPNS/SFNP guideline on the anticoagulant 
treatment of cerebral sinovenous thrombosis in children 
and neonates. Eur J Paediatr Neurol 2012; 16: 219-
228.
14. Thorell SE, Parry-Jones AR, Punter M, Hurford R, 
Thachil J. Cerebral venous thrombosis-a primer for 
the haematologist. Blood Rev 2015; 29: 45-50.
15. Bektaş Ö, Teber S, Akar N, et al. Cerebral sinovenous 
thrombosis in children and neonates: clinical experience, 
laboratory, treatment, and outcome. Clin Appl Thromb 
Hemost 2015; 21: 777-782.
16. Fitzgerald KC, Williams LS, Garg BP, Carvalho KS, 
Golomb MR. Cerebral sinovenous thrombosis in the 
neonate. Arch Neurol 2006; 63: 405-409.
17. Gentilomo C, Franzoi M, Laverda AM, Suppiej 
A, Battistella PA, Simioni P. Cerebral sinovenous 
thrombosis in children: thrombophilia and clinical 
outcome. Thromb Res 2008; 121: 589-591.
Volume 59 • Number  1  Neonatal Cerebral Sinovenous Thrombosis  75
